Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$21.61 USD
+0.40 (1.89%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $21.65 +0.04 (0.19%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
KNSA 21.61 +0.40(1.89%)
Will KNSA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KNSA
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice
Other News for KNSA
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
Kiniksa Pharmaceuticals files for $400M mixed shelf
Kiniksa files $400M mixed securities shelf
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis